文献速递心力衰竭与心肌病冠心病

恩格列净在心力衰竭不同肾功能水平中的心肾获益:EMPEROR-Reduced 研究 insights

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
PubMed 文献 · Circulation · 2020-10-23

EMPEROR-Reduced 研究预设分析探讨恩格列净在射血分数降低的心力衰竭患者中跨肾功能谱的心血管和肾脏结局。共随机 3730 例患者,53% 合并慢性肾脏病(CKD)。恩格列净在有或无 CKD 患者中均降低主要复合终点和总心衰住院风险,并减缓 eGFR 下降,且在广泛基线肾功能范围内(包括 eGFR 低至 20 ml/min/1.73 m²)效果一致。

要点

  • 恩格列净在有或无 CKD 的 HFrEF 患者中均降低心血管死亡或心衰住院风险。
  • 恩格列净减缓肾功能下降,并降低复合肾脏结局风险,不受基线 CKD 状态影响。
  • 恩格列净在广泛基线肾功能(包括 eGFR 低至 20)中疗效一致且耐受性良好。

核心结论

  • 在 EMPEROR-Reduced 研究中,恩格列净在有或无 CKD 的患者中均改善关键疗效终点并减缓肾功能下降速率,且不受基线肾功能损害严重程度影响。

研究设计与样本

  • EMPEROR-Reduced 研究的事先指定分析,将患者按基线有无 CKD(eGFR <60 ml/min/1.73 m² 或白蛋白与肌酐比值 >300 mg/g)分类。
  • 共随机 3730 例患者至恩格列净或安慰剂组,其中 1978 例(53%)合并 CKD,中位随访 16 个月。

主要发现

  • 恩格列净降低主要终点(心血管死亡或心衰住院)在有 CKD 患者中 HR=0.78(95% CI 0.65-0.93),无 CKD 患者中 HR=0.72(95% CI 0.58-0.90),交互 P=0.63。
  • 恩格列净减少总心衰住院在有 CKD 患者中 HR=0.78(95% CI 0.65-0.93),无 CKD 患者中 HR=0.72(95% CI 0.58-0.90),交互 P=0.63。
  • 恩格列净减缓 eGFR 下降斜率:有 CKD 患者中差异 1.11(95% CI 0.23-1.98)ml/min/1.73 m²/年,无 CKD 患者中差异 2.41(95% CI 1.49-3.32)ml/min/1.73 m²/年。
  • 复合肾脏结局风险降低在有 CKD 患者中 HR=0.53(95% CI 0.31-0.91),无 CKD 患者中 HR=0.46(95% CI 0.22-0.99)。
  • 恩格列净对主要复合终点和关键次要终点的效果在广泛基线肾功能范围内一致,包括 eGFR 低至 20 ml/min/1.73 m² 的患者;在 CKD 患者中耐受性良好。

关键数值与推荐

  • CKD 定义:基线 eGFR <60 ml/min/1.73 m² 或白蛋白与肌酐比值 >300 mg/g。
  • 主要终点:心血管死亡或心衰住院复合终点;关键次要终点:总心衰住院和 eGFR 斜率。
  • 预设复合肾脏结局定义:eGFR 持续大幅下降、慢性透析或移植。

临床怎么用

  • 对于 HFrEF 患者,无论是否合并 CKD 或基线肾功能损害程度如何,均可考虑使用恩格列净以降低心血管事件和减缓肾功能下降。
  • 恩格列净在 CKD 患者中耐受性良好,支持在广泛肾功能范围内使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) hospitalization and total HF hospitalizations, and slowed the progressive decline in kidney function in patients with HF and a reduced ejection fraction, with and without diabetes. We aim to study the effect of empagliflozin on cardiovascular and kidney outcomes across the spectrum of kidney function. METHODS: In this prespecified analysis, patients were categorized by the presence or absence of chronic kidney disease (CKD) at baseline (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2 or albumin-to-creatine ratio >300 mg/g). The primary and key secondary outcomes were: (1) a composite of cardiovascular death or HF hospitalization (primary outcome); (2) total HF hospitalizations; and (3) eGFR slope. The direct impact on kidney events was investigated by a prespecified composite kidney outcome (defined as a sustained profound decline in eGFR, chronic dialysis, or transplant). The median follow-up was 16 months. RESULTS: Of 3730 patients who were randomized to empagliflozin or placebo, 1978 (53%) had CKD. Empagliflozin reduced the primary outcome and total HF hospitalizations in patients with and without CKD: hazard ratio (HR)=0.78 (95% CI, 0.65-0.93) and HR=0.72 (95% CI, 0.58-0.90), respectively (interaction P=0.63). Empagliflozin slowed the slope of eGFR decline by 1.11 (0.23-1.98) ml/min/1.73 m2/yr in patients with CKD and by 2.41 (1.49-3.32) ml/min/1.73 m2/yr in patients without CKD. The risk of the composite kidney outcome was reduced similarly in patients with and without CKD: HR=0.53 (95% CI, 0.31-0.91) and HR=0.46 (95% CI, 0.22-0.99), respectively. The effect of empagliflozin on the primary composite outcome and key secondary outcomes was consistent across a broad range of baseline kidney function, measured by clinically relevant eGFR subgroups or by albuminuria, including patients with eGFR as low as 20 ml/min/1.73 m2. Empagliflozin was well tolerated in CKD patients. CONCLUSIONS: In EMPEROR-Reduced, empagliflozin had a beneficial effect on the key efficacy outcomes and slowed the rate of kidney function decline in patients with and without CKD, and regardless of the severity of kidney impairment at baseline. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation. 2020. PMID: 33095032. doi:10.1161/CIRCULATIONAHA.120.051685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。